These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 20497550)

  • 1. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes.
    Belisle JA; Horibata S; Jennifer GA; Petrie S; Kapur A; André S; Gabius HJ; Rancourt C; Connor J; Paulson JC; Patankar MS
    Mol Cancer; 2010 May; 9():118. PubMed ID: 20497550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mucin MUC16 (CA125) binds to NK cells and monocytes from peripheral blood of women with healthy pregnancy and preeclampsia.
    Tyler C; Kapur A; Felder M; Belisle JA; Trautman C; Gubbels JA; Connor JP; Patankar MS
    Am J Reprod Immunol; 2012 Jul; 68(1):28-37. PubMed ID: 22380506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells.
    Gubbels JA; Felder M; Horibata S; Belisle JA; Kapur A; Holden H; Petrie S; Migneault M; Rancourt C; Connor JP; Patankar MS
    Mol Cancer; 2010 Jan; 9():11. PubMed ID: 20089172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125).
    Belisle JA; Gubbels JA; Raphael CA; Migneault M; Rancourt C; Connor JP; Patankar MS
    Immunology; 2007 Nov; 122(3):418-29. PubMed ID: 17617155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of a novel microscopic technique for quantifying CA125 binding to circulating mononuclear cells in longitudinal specimens during treatment for ovarian cancer.
    Lakatos K; González G; Hoballah J; Brooker J; Jeong S; Evans C; Krauledat P; Hansen WP; Elias KM; Patankar M; Fülöp V; Konstantinopoulos PA; Cramer DW
    J Ovarian Res; 2022 Feb; 15(1):28. PubMed ID: 35219339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC16 stimulates neutrophils to an inflammatory and immunosuppressive phenotype in ovarian cancer.
    Wu Y; Liu Q; Xie Y; Zhu J; Zhang S; Ge Y; Guo J; Luo N; Huang W; Xu R; Liu S; Cheng Z
    J Ovarian Res; 2023 Aug; 16(1):181. PubMed ID: 37644468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Siglec-7 expression is reduced on a natural killer (NK) cell subset of obese humans.
    Rosenstock P; Horstkorte R; Gnanapragassam VS; Harth J; Kielstein H
    Immunol Res; 2017 Oct; 65(5):1017-1024. PubMed ID: 28786023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells.
    Avril T; Floyd H; Lopez F; Vivier E; Crocker PR
    J Immunol; 2004 Dec; 173(11):6841-9. PubMed ID: 15557178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Siglec-9 defines and restrains a natural killer subpopulation highly cytotoxic to HIV-infected cells.
    Adeniji OS; Kuri-Cervantes L; Yu C; Xu Z; Ho M; Chew GM; Shikuma C; Tomescu C; George AF; Roan NR; Ndhlovu LC; Liu Q; Muthumani K; Weiner DB; Betts MR; Xiao H; Abdel-Mohsen M
    PLoS Pathog; 2021 Nov; 17(11):e1010034. PubMed ID: 34762717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9.
    Ikehara Y; Ikehara SK; Paulson JC
    J Biol Chem; 2004 Oct; 279(41):43117-25. PubMed ID: 15292262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
    Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
    Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes.
    Nicoll G; Ni J; Liu D; Klenerman P; Munday J; Dubock S; Mattei MG; Crocker PR
    J Biol Chem; 1999 Nov; 274(48):34089-95. PubMed ID: 10567377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.
    Crawford A; Haber L; Kelly MP; Vazzana K; Canova L; Ram P; Pawashe A; Finney J; Jalal S; Chiu D; Colleton CA; Garnova E; Makonnen S; Hickey C; Krueger P; DelFino F; Potocky T; Kuhnert J; Godin S; Retter MW; Duramad P; MacDonald D; Olson WC; Fairhurst J; Huang T; Martin J; Lin JC; Smith E; Thurston G; Kirshner JR
    Sci Transl Med; 2019 Jun; 11(497):. PubMed ID: 31217340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced Siglec-7 expression on NK cells predicts NK cell dysfunction in primary hepatocellular carcinoma.
    Tao L; Wang S; Yang L; Jiang L; Li J; Wang X
    Clin Exp Immunol; 2020 Aug; 201(2):161-170. PubMed ID: 32319079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and functional characterization of a Siglec-7 counter-receptor on K562 cells.
    Yoshimura A; Asahina Y; Chang LY; Angata T; Tanaka H; Kitajima K; Sato C
    J Biol Chem; 2021; 296():100477. PubMed ID: 33640457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance.
    Jandus C; Boligan KF; Chijioke O; Liu H; Dahlhaus M; Démoulins T; Schneider C; Wehrli M; Hunger RE; Baerlocher GM; Simon HU; Romero P; Münz C; von Gunten S
    J Clin Invest; 2014 Apr; 124(4):1810-20. PubMed ID: 24569453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of sialic acid diversity in cancer- and non-cancer related CA125 antigen using sialic acid-binding Ig-like lectins (Siglecs).
    Mitic N; Milutinovic B; Jankovic M
    Dis Markers; 2012; 32(3):187-94. PubMed ID: 22377735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probing the cis interactions of the inhibitory receptor Siglec-7 with alpha2,8-disialylated ligands on natural killer cells and other leukocytes using glycan-specific antibodies and by analysis of alpha2,8-sialyltransferase gene expression.
    Avril T; North SJ; Haslam SM; Willison HJ; Crocker PR
    J Leukoc Biol; 2006 Oct; 80(4):787-96. PubMed ID: 16857734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Frequency of Dysfunctional Siglec-7
    Sakamoto Y; Yoshio S; Doi H; Mori T; Matsuda M; Kawai H; Shimagaki T; Yoshikawa S; Aoki Y; Osawa Y; Yoshida Y; Arai T; Itokawa N; Atsukawa M; Ito T; Honda T; Mise Y; Ono Y; Takahashi Y; Saiura A; Taketomi A; Kanto T
    Front Immunol; 2021; 12():603133. PubMed ID: 33692781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viewing Siglecs through the lens of tumor immunology.
    Fraschilla I; Pillai S
    Immunol Rev; 2017 Mar; 276(1):178-191. PubMed ID: 28258691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.